BioXcel Therapeutics, Inc.:
Clinical stage company utilizing AI technology platform to identify improved therapies in neuroscience and immuno-oncology. BXCL501 (sublingual dexmedetomidine): Phase 3 trials ongoing for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). Topline data expected mid-2020; Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. Data expected mid-2020; BXCL701 (innate immunity activator): Phase 1b/2 ongoing of BXCL701 and KEYTRUDA for Prostate Cancer (tNEPC).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
555 Long Wharf Drive
5th Floor
New Haven, Connecticut 06511
United States
5th Floor
New Haven, Connecticut 06511
United States
Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13
- Vimal Mehta, Dr, CEO
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of BioXcel Therapeutics, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| DNCA Finance SA | 5.70 | 892,453 | 47.67 | Stakes | 2020-03-03 |
| Artemis Investment Management LLP | 5.02 | 786,958 | 42.04 | 13F | 2020-03-31 |
| Ikarian Capital LLC | 4.43 | 693,716 | 37.06 | 13F | 2020-03-31 |
| Fidelity Management & Research Co. LLC | 3.86 | 605,490 | 32.35 | 13F | 2020-03-31 |
| The Vanguard Group, Inc. | 3.22 | 504,899 | 26.97 | Funds | 2020-05-31 |
| Vanguard Group, Inc. (Subfiler) | 3.03 | 475,102 | 25.38 | 13F | 2020-03-31 |
| Acuta Capital Partners LLC | 2.01 | 315,000 | 16.83 | 13F | 2020-03-31 |
| Driehaus Capital Management LLC | 1.91 | 299,932 | 16.02 | 13F | 2020-03-31 |
| Massachusetts Financial Services Co. | 1.75 | 274,404 | 14.66 | 13F | 2020-03-31 |
| BlackRock Fund Advisors | 1.58 | 247,319 | 13.21 | 13F | 2020-03-31 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.